Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
R-Pharm
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced or metastatic HER2+ breast cancer not previously treated with chemotherapy or trastuzumab.
Subjects who had received prior (neo)adjuvant chemotherapy or trastuzumab were eligible except if they relapsed within 12 months after the last dose of a taxane or trastuzumab given as (neo)adjuvant therapy.
Measurable disease
Left Ventricular Ejection Fraction (LVEF) ≥50%
You may not be if
Prior chemotherapy or trastuzumab for metastatic breast cancer (MBC)
Relapse within 1 year after (neo)adjuvant taxane or trastuzumab
Neuropathy \> Grade 1
Significant cardiovascular disease
Any brain metastases
Clareo Health | A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
